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Schistosomiasis remains a serious zoonotic disease in China and the Philippines. Water
buffalo and cattle account for the majority of transmission. Vaccination of water buffalo
is considered a key strategy to reduce disease prevalence. Previously, we showed that
vaccination of water buffalo with SjC23 or SjCTPI plasmid DNA vaccines, induced 50%
efficacy to challenge infection. Here, we evaluated several parameters to determine if we
can develop a two dose vaccine that maintains the efficacy of the three dose vaccine. We
performed four trials evaluating: (1) lab produced vs. GLP grade vaccines, (2) varying the
time between prime and boost, (3) the influence of an IL-12 adjuvant, and (4) a two dose
heterologous (DNA-protein) prime-boost. We found the source of the DNA vaccines did
not matter, nor did increasing the interval between prime and boost. Elimination of the
IL-12 plasmid lowered homologous DNA-DNA vaccine efficacy. A major finding was that
the heterologous prime boost improved vaccine efficacy, with the prime-boost regimen
incorporating both antigens providing a 55% reduction in adult worms and 53% reduction
in liver eggs. Vaccinated buffalo produced vaccine-specific antibody responses. These
trials suggest that highly effective vaccination against schistosomes can be achieved
using a two dose regimen. No adjuvants were used with the protein boost, and the
potential that addition of adjuvant to the protein boost to further increase efficacy should
be evaluated. These results suggest that use of these two schistosome vaccines can be
part of an integrated control strategy to reduce transmission of schistosomiasis in Asia.
Keywords: Schistosoma japonicum, DNA vaccine, SjTPI, SjC23, heterologous prime-boost, water buffalo
INTRODUCTION
Schistosomiasis continues to be a serious public health problem worldwide, with more than 200
million people infected and with an estimated 700 million people in 74 countries at risk of infection
(1). Three species, Schistosoma japonicum, S. mansoni, and S. haematobium, cause the majority of
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regions of southeast Asia (1). Unlike S. mansoni and S.
haematobium, S. japonicum is a zoonotic disease (2–5).
Epidemiological studies have shown that bovines, particularly
water buffalo play a major role in the transmission of
schistosomiasis in China and the Philippines (6, 7). Despite
more than 50 years of intensive control efforts, including the
World Bank Schistosomiasis Control Project from 1992 to 2001,
schistosomiasis remains a major public health concern in these
regions, with over one million Chinese currently infected and
another 40 million living in areas at risk of infection (4, 8).
The majority (>80%) of schistosomiasis cases occur around the
Dongting and Poyang lakes and themarshland regions of Hunan,
Jiangxi, Anhui, Hubei, and Jiangsu Provinces of China, where
elimination of transmission has proved difficult (9–12).
Schistosomiasis control in China includes simultaneous
praziquantel (PZQ) treatment of humans and water buffalo
and reducing the number of water buffalo in endemic areas
by replacing them with cattle or motorized tractors (13, 14).
These control measures are time consuming, expensive, and for
praziquantel treatment, recurring annually. A more sustainable
option would be development of an integrated control program
that, in addition to praziquantel treatment, adds vaccination
of water buffalo and cattle to further reduce transmission
of S. japonicum from bovines, potentially leading to long-
term sustainable control of schistosomiasis (7, 15–17). It is
important to vaccinate cattle in endemic settings as they are
more susceptible to schistosome infection than water buffalo
(18). In this regard, a mathematical model of schistosome
transmission predicts that schistosome vaccines capable of
reducing schistosome fecal egg output from water buffalo/cattle
by 40% will lead to a significant reduction in transmission of
schistosomiasis (3, 16).
Efficacy of the SjTPI and SjC23 plasmid DNA vaccines in
water buffalo was previously shown to be 50%when administered
three times using an IL-12 plasmid DNA adjuvant (16, 19).
In the current study, our goal was to evaluate GLP quality
plasmid DNA vs. lab-produced plasmid DNA and to reduce
the vaccine regimen from three doses to two coincident with
increased efficacy for these two vaccines. We found vaccine
efficacy of plasmid DNA vaccines to be the same independent
of the source of the plasmid DNAs. We found that extending
the time between prime and boost did not change levels of
plasmid DNA vaccine efficacy. We did note the positive influence
on vaccine efficacy when a pIL-12 plasmid DNA was used
with the pSjC23. Importantly, we observed that the two-dose,
heterologous prime-boost regimen induced the highest levels
of efficacy we have seen in water buffalo trials. Here, the rec
SjC23 and SjCTPI proteins were administered in saline without
adjuvant, suggesting that additional vaccine trials in buffalo
Abbreviations: pVAX, empty plasmid DNA control vector; pSjC23-hsp70,
plasmid DNA encoding C23 gene of Schistosoma japonicum fused to bovine
heat shock protein 70; pSjC23, plasmid DNA encoding C23 gene of Schistosoma
japonicum; pSjTPI, plasmid DNA encoding TPI gene of Schistosoma japonicum;
rSjC23, recombinant C23 protein of Schistosoma japonicum; rSjTPI, recombinant
TPI protein of Schistosoma japonicum; pIL-12, plasmid DNA encoding human
interleukin 12 (IL-12); PZQ, praziquantel; EPG, eggs per gram; MPG, miracidia
per gram.
should be performed to ascertain whether a recombinant protein
homologous prime-boost vaccine regimen with adjuvant will
yield significantly higher levels of efficacy than reported here.
MATERIALS AND METHODS
Buffalo and Trial Site
Water Buffalo were purchased from Huilong county, Hunan
province, from an area with no history of schistosomiasis
transmission, and transported to the field site. Age, sex and
weight of the different water buffaloes used in this study are
summarized in the Supplementary Tables 1–4. Upon arrival at
the field site, the buffalo were quarantined for 4 weeks, confirmed
schistosome-free by the miracidial hatching test and ELISA,
and treated with levamisole to eliminate other gastrointestinal
geohelminths, as described (16). Water buffalo were then tagged
with an identification number on the collar, the right ear, and
into one of the horns, then divided randomly into different trial
groups such that buffalo in each trial cohort had similar numbers
of male and female buffalo and were of similar age and weight
(Supplementary Table 1). The study site selected for the vaccine
trials was Huaqiao village, Linxiang city, Hunan province.
DNA Vaccines and Recombinant Proteins
All DNA vaccine constructs were constructed as described in
Da’dara et al. (16). GLP standard plasmids (SjC23-Hsp70 and
SjTPI-Hsp70) including control plasmid pVAX1, and pUMVC3-
hIL-12 plasmid DNA encoding human IL-12 (pIL-12) were
manufactured by Aldevron (Fargo, ND). Recombinant SjTPI
(rSjTPI) and SjC23 (rSjC23) were purified using similar protocols
as previously described (16). Briefly, for SjC23, the large
extracellular hydrophilic domain (amino acids 108–183) of
SjC23 (SjC23-loop) was expressed in Escherichia coli using the
prokaryotic expression plasmid pET32b (Novagen, Madison,WI,
USA). For SjCTPI, the pTrcHisB plasmid (Invitrogen) was used
to produce full-length recombinant SjCTPI. Recombinant SjC23
and SjCTPI proteins were purified using His-Trap HP columns
(GE Healthcare, Piscataway, NJ, USA). Purified recombinant
proteins were analyzed by SDS-PAGE and Western blotting.
Vaccine Study Design, Vaccination, and
Challenge Infection
Initially, we compared immunogenicity and efficacy of in-
lab produced SjC23 plasmid DNA vaccines to commercially
produced, GLP grade, SjC23 plasmid DNA vaccines. The trial
was a randomized double-blinded study, comprised of 45
buffalo divided randomly into three groups. Plasmid DNAs were
coded by an independent laboratory at the Harvard School of
Public Health (HSPH), then shipped to China. Animals were
immunized intramuscularly with 1ml of 300 µg of schistosome-
DNA or control pVAX vaccine plus 300µg of IL-12 plasmidDNA
for priming (Figure 1). One month after the last immunization,
water buffalo were challenged with 1,000 freshly shed cercariae
kindly provided by Jiangsu Institute of Parasitic Diseases, China.
Eight weeks post-challenge, water buffalo were euthanized and
adult worm burdens determined by perfusion. Additionally,
when possible, identical portions of liver lobes were obtained
Frontiers in Immunology | www.frontiersin.org 2 February 2019 | Volume 10 | Article 284
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FIGURE 1 | Evaluation of commercially produced, GLP grade DNA vaccine pSjC23-hsp70. (A) Buffalo were vaccinated with saline or pSjC23-hsp70 plasmid
produced by Harvard or Aldevron three times at 1 month intervals. All animals were also given pIL-12 adjuvant plasmid at the first (prime) vaccination. One month after
the third vaccination, buffalo were challenged with 1,000 cercariae. Two months post challenge, buffalo were perfused. (B) Worm and (C) fecal miracidia burdens
were measured. The average and standard deviations are graphed. Percent reductions and total animals per group are listed within each bar. **p < 0.02, ***p < 0.01
by one-way ANOVA with Turkey’s post-test.
to determine liver egg burdens, and fresh fecal samples were
obtained to determine fecal egg counts and miracidial hatching
rates as previously described (16).
The second goal of this study was to determine if extending
the time between prime and boost would improve DNA
vaccine efficacy. Animals were immunized intramuscularly with
schistosome-DNA or control DNA vaccines as previously
described (Figure 2A). We compared 1- and 3-month
intervals between prime and boost. One month after the
last immunization, water buffalo were challenged with 800
cercariae freshly shed from native/local, infected snails.
We then examined the importance of the IL-12 plasmid
DNA for induction of optimal levels of efficacy. Buffalo were
immunized as previously described with schistosome-DNA or
control DNA vaccines with or without the pUMVC3-hIL-12
plasmid DNA (Figure 3). The pUMVC3-hIL12 was administered
at the prime only. One month after the last immunization, water
buffalo were challenged with 800 cercariae.
Finally, we evaluated efficacy of a heterologous plasmid
DNA prime with a recombinant protein boost. In this trial,
we employed combination SjTPI/SjC23 vaccines. Buffalo were
primed as described with 300 µg of both the SjC23 and SjTPI
DNA vaccines or control DNA vaccine. Booster vaccination was
with plasmid DNAs or with 100 µg each, recombinant SjC23 and
SjTPI proteins (Figure 4A). One control group received control
pVAX DNA as prime and were then boosted with recombinant
antigens. One month after the last immunization, water buffalo
were challenged with 1,000 freshly shed cercariae.
Water Buffalo Perfusion and Analysis of
Worm Burden
Two months post-challenge, water buffalo were weighed then
euthanized. Adult worms were obtained from the portal vein
by perfusion of the descending thoracic aorta with physiologic
saline. Worms trapped in intestinal tissue or caught up in tissues
near where the portal vein was cut, were collected by hand and
counted. All adult worms recovered from each water buffalo were
counted and recorded as total worm burdens.
S. japonicum Eggs in Liver
Two samples from the left lobe and one sample from the right
lobe were taken from the livers of each water buffalo andweighed.
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FIGURE 2 | Comparison of inter-vaccination interval length. (A) Buffalo were vaccinated with saline, pVAX control or pSjC23-hsp70 plasmid three times at 1 month
(Regular) or 3 month (Extended) intervals. All groups except for the saline injection were also given pIL-12 adjuvant plasmid at the first (prime) vaccination. One
month after the third vaccination, buffalo were challenged with 800 cercariae. Two months post challenge, buffalo were perfused. (B) Worm, (C) liver egg, and (D)
fecal miracidia burdens were measured. The average and standard deviations are graphed. Percent reductions and total animals per group are listed within each bar.
**p < 0.01, ***p < 0.001 by one-way ANOVA with Turkey’s post-test.
Each piece was placed in 20ml of 4% (w/v) KOH for 2 days
at 37◦C. The suspension was then agitated to re-suspend the
mixture, 1ml of the liver suspension was collected, centrifuged at
3,000 rpm for 1min, the pellet re-suspended in 200µl of PBS and
the total eggs present were counted under a microscope. Using
the average of three separate samples, the number of eggs per
gram of liver tissue were calculated for each animal.
S. japonicum Eggs in Stool Samples
Three fecal samples were collected from the rectum of each water
buffalo 2 days and 1 day prior to perfusion and again on the day
of perfusion. For each fecal sample, the number of eggs per gram
(EPG) of stool was determined by microscopy and the number
of hatched miracidia per gram (MPG) of stool was determined as
previously described (20).
Serological Immunoassay
Serum samples from four different buffalo from each group were
randomly selected then analyzed by Western blot and ELISA
to determine the antigen-specific antibody levels in sera from
vaccinated buffalo as described (16).
Statistical Analysis
GraphPad Prism version 5 was used for statistical analysis.
One-way ANOVA with Tukey’s post-test or two-way ANOVA
and Bonferroni’s post-test were used to identify the significance
between various groups. Statistical significance was accepted
at p < 0.05.
RESULTS
GLP Grade DNA Vaccine Sj23-Hsp70 Has
Similar Efficacy to In-lab Produced DNA
Vaccine
In order to meet potential larger vaccine doses and reduce
costs, we contracted with Aldevron, a leading company in
the production of plasmid DNA and recombinant proteins,
to produce each DNA vaccine and the control plasmid DNA
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FIGURE 3 | Determination of pIL-12 adjuvant requirement. (A) Buffalo were vaccinated with pVAX control or pSjC23-hsp70 plasmid three times at 3 month intervals.
Half of the animals receiving pSjC23-hsp70 were also given pIL-12 adjuvant plasmid at the first (prime) vaccination. One month after the third vaccination, buffalo were
challenged with 800 cercariae. Two months post challenge, buffalo were perfused. (B) Worm, (C) liver egg, and (D) fecal miracidia burdens were measured. The
average and standard deviations are graphed. Percent reductions and total animals per group are listed within each bar. **p < 0.01, ***p < 0.001 by one-way ANOVA
with Turkey’s post-test.
under GLP conditions. To determine if GLP grade production
would influence vaccine efficacy, we compared the Aldevron
GLP grade vaccines to our in-house DNA vaccines using
the regimen outlined in Figure 1A. Vaccination of water
buffalo with the Sj23-Hsp70 construct produced at the Harvard
School of Public Health or from Aldevron resulted in nearly
identical levels of efficacy, 23.5 and 25.7% respectively, with
no significant differences of mean adult worm burdens (p =
0.816) between these two vaccine groups as determined by
One-ANOVA with Turkey’s post-test (Figure 1B). Interestingly,
we also observed lower reductions in miracidial hatching rates
of 19 and 10% respectively (Figure 1C). Table 1 summarizes
this data.
Extending the Time Between Priming and
Boosting May Reduce DNA/DNA Vaccine
Efficacy
Previous studies have reported that extending the interval
between priming and boosting can influence vaccine efficacy
(21–24). To test this, we increased the time between prime
and boost from 1 to 3 months. Using the SjC23 DNA/DNA
prime boost-boost with 1 or 3-month intervals, we found that
efficacy, as determined by worm burden, liver eggs/gram and
fecal eggs/gram, was higher in animals where boosts were
given at 1-month intervals (Table 2 and Figure 2). We observed
significant reductions in adult worm burdens of 37.2 and
41.2% and reductions in eggs/gram liver of 30.4 and 37.5%
for SjC23 DNA vaccinated groups at extended (3 month)
or regular (1 month) intervals, respectively (Figures 2B,C).
The reduction in eggs per gram stools of 31.5 and 45.8%
for extended and regular month interval groups (Figure 2D).
However, there was no statistically significant difference between
the extended and the regular immunization regimen in all
measured parameters.
Influence of IL-12 Plasmid DNA on DNA
Vaccine Efficacy
IL-12 is an important cytokine that has the potential to activate
natural killer cells and promote cytolytic T cell proliferation and
has been used as an adjuvant to promote Th1-type and cellular
immune responses in various DNA vaccine trials (25–29). We
previously reported that administration of IL-12 with the boost
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FIGURE 4 | Assessment of heterologous vaccination regimen. (A) Buffalo were vaccinated with a DNA prime, followed by a recombinant protein boost 3 months later,
as indicated. All animals were also given pIL-12 adjuvant plasmid at the first (prime) vaccination. One month after the booster vaccination, buffalo were challenged with
1,000 cercariae. Two months post challenge, buffalo were perfused. (B) Worm, (C) liver egg, and (D) fecal miracidia burdens were measured. The average and
standard deviations are graphed. Percent reductions and total animals per group are listed within each bar. *p < 0.05, ****p < 0.0001 by one-way ANOVA with
Turkey’s post-test.
enhanced host immunity and better protective efficacy in water
buffalo (16, 19). However, we did not know if our DNA vaccines
would retain similar protection without IL-12. The vaccination
trial in water buffalo performed here showed that addition of
Plasmid DNA encoding IL-12 enhanced all aspects of DNA
vaccine efficacy (Table 3). Adult worm burdens were reduced by
46.6% in buffalo co-administered plasmid DNA IL-12 compared
to 30.2% in buffalo vaccinated with SjC23 plasmid DNA and
no IL-12 (Figure 3B). Similarly, the number of eggs/gram liver
tissue was reduced 45% in buffalo co-administered plasmid
DNA IL-12 compared to 31% in buffalo vaccinated with SjC23
plasmid DNA and no IL-12 (Figure 3C). A similar influence
of co-administering plasmid DNA encoding IL-12 was seen in
eggs/gram stool (Figure 3D). Overall, efficacy data from theDNA
prime-boost experiments evaluating interval between prime and
boost or value of the IL-12 plasmid were similar to what we
previously reported for our plasmid DNA vaccines (16) and show
that co-administration of the IL-12 encoding plasmid enhances
DNA vaccine efficacy, yet not statistically significant from the no
IL-12 plasmid.
Boosting With Recombinant SjTPI and/or
SjC23 Improves Vaccine Efficacy
Boosting with recombinant proteins following a DNA prime
immunization elicits a broad humoral immune response and
enhances the cell-mediated immune responses in mice and non-
human primates (30–34). Therefore, here we moved from a
three-dose plasmid DNA vaccine regimen to a two-dose plasmid
DNA prime and recombinant protein boost regimen with a 3-
month interval between prime and boost (Figure 4A). Groups
of water buffalo were primed with pVAX control plasmid DNA,
SjC23-Hsp70 plasmid DNA, or with a combination of SjC23-
Hsp70 and SjTPI-Hsp70 plasmid DNAs. Three months post-
prime, groups of water buffalo were boosted with recSjC23 or
a combination of recSjC23 and recSjTPI (Figure 4). The results
of these trials demonstrated that buffalo only receiving recSjC23
following the control pVAX prime had adult worm burdens
reduced by 32.2% compared to pVAX primed and boosted buffalo
(Table 4; Figure 4B). Similarly, eggs/gram liver were reduced by
31.0% in buffalo that only received the SjC23 boost following
control pVAX prime (Figure 4C). Vaccine efficacy significantly
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Total worms per animal (X ± SD) Reduction and Statistics n Eggs per gram feces (X ± SD) Reduction and Statistics
pVAX 10 565.7 ± 134.208 14 28.506 ± 13.927
Harvard 13 431.692 ± 137.602 23.5% p < 0.01 15 22.976 ± 11.112 19.3% n.s.
Aldevron 14 420.286 ± 114.603 25.7% p < 0.02 15 25.570 ± 15.623 10.3% n.s.
†
Several buffalo were excluded due to improper perfusion.
pIL-12 was administered at the prime for all groups.
p-value compared to pVAX by one-way ANOVA and Turkey’s post-test.
TABLE 2 | Comparison of time between vaccinations: 1 month (regular) or 3 months (extended).
Worms Liver eggs Miracidia
Group
(time between injections)
n Total worms per













9 454.44 ± 19.42 464.11 ± 98.43 26.00 ± 7.00
pVAX
(extended)
9 454.67 ± 15.18 486.11 ± 103.99 26.67 ± 6.00
pSjC23-Hsp70 (extended) 11 285.27 ± 30.19 37.23%
p < 0.0001
323.00 ± 40.91 30.4%
p < 0.0001




11 267.27 ± 30.46 41.19%
p < 0.0001
290.09 ± 45.68 37.5%
p < 0.0001
14.09 ± 2.43 45.81%
p < 0.001
pIL-12 was administered at the prime for all groups but mock.
p-value compared to mock by one-way ANOVA and Turkey’s post-test.
No significant difference between extended and regular.
increased in the two-dose regimen when buffalo were primed
with SjC23-Hsp70 DNA then boosted with recSjC23. Here, adult
worm burdens were reduced by 50.0% compared to controls
and eggs/gram liver were reduced 47.0% compared to control
vaccinated buffalo. However, we observed the highest levels of
efficacy in this two-dose regimen trial when buffalo were primed
with the combination of SjC23-Hsp70 and SjTPI-Hsp70 plasmid
DNAs followed by boost with a combination of recSjC23 and
recSjTPI. This combination yielded the highest level of vaccine
efficacy that we have observed to date for these candidate vaccines
in water buffalo. Adult worm burdens were reduced by 55.1%
and eggs/gram liver by 53.2% compared to levels in control
vaccinated buffalo (Figures 4B,C). Using DNA prime/protein
boost, the reduction in worm burdens (Figure 4B), eggs in liver
tissues (Figure 4C) and hatched miracidia in stool (Figure 4D)
were dramatic compared to that in the control vaccinated group
(p < 0.0001).
We next evaluated sera from control and immunized animals
for anti-SjC23 or SjTPI specific antibodies using Western blots
and ELISA (Figure 5). We randomly picked four or more
individual serum samples from each group to detect antigen-
specific antibodies using Western blot. Sera from animals
primed with SjC23-Hsp70 alone in in combination with SjTPI-
Hsp70 then boosted with the correlate recombinant antigen
elicited specific antibody responses to the respective antigens
(Figure 5A). In contrast, sera from animals primed with the
control pVAX plasmid and boosted with either pVAX or
recombinant proteins did not react with rSjC23 (Figure 5A
left panel, lanes 1-8) or rSjTPI (Figure 5A right panel, lanes
1-8). Individual sera collected at different time points from
animals were used in ELISA. ELISA results showed that antibody
levels are significantly increased after boosting with recombinant
proteins in group 3 and 4 (Figure 5B).
DISCUSSION
Over the past 60 years, despite great progress in China to control
S. japonicum, national surveys have shown that prevalence in
humans in areas of endemicity did not substantially change from
1995 (4.9%) to 2004 (5.1%) (35). The current control strategy
for schistosomiasis in humans and water buffalo has provided
prevalence at the targeted 5% level. The targeted level was revised
with the goal of reducing prevalence and infection to under 1%
by 2015 (14).
Bovines (cattle and water buffalo) are the major reservoirs
for S. japonicum infection in China and the Philippines, with
estimates that 75–90% of egg contamination comes from this
source. Maintaining the current praziquantel-based control
strategy for bovines in the Lakes and Marsh regions of China
will be difficult and costly. In addition, there is always the
possibility that new endemic regions will be found in China.
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TABLE 3 | The role of IL-12.
Worms Liver eggs Miracidia
Group n Total worms per
animal (X ± SD)
Reduction (%) Eggs per gram
liver (X ± SD)
Reduction (%) Eggs per gram
feces (X ± SD)
Reduction (%)
pVAX 9 348.56 ± 55.60 404.23 ± 72.15 22.40 ± 4.97
pSjC23 9 243.33 ± 85.79 30.19%
p < 0.01
279.02 ± 83.53 30.97%
p < 0.001
16.07 ± 6.81 28.26%
p < 0.5
pSjC23/pIL-12 9 186.00 ± 56.20 46.64%
p < 0.0001
219.54 ± 64.75 45.69%
p < 0.0001
12.75 ± 3.60 43.08%
p < 0.01
pIL-12 was only administered at the prime.
p-value compared to pVAX by one-way ANOVA and Turkey’s post-test.
Addition of IL-12 encoding plasmid enhanced all vaccine efficacies, yet the difference was not statistically significant.
TABLE 4 | DNA prime with recombinant protein boost.
Worms Liver eggs Miracidia
Group
(prime + boost)
n Total worms per
animal (X ± SD)
Reduction (%) Eggs per gram
liver (X ± SD)
Reduction (%) Eggs per gram
feces (X ± SD)
Reduction (%)
pVAX + pVAX 9 393.33 ± 32.99 444.44 ± 76.01 33.78 ± 4.30
pVAX + rSjC23 9 266.67 ±14.73 32.2%
p < 0.0001




pSjC23 + rSjC23 9 198.00 ± 18.74 49.66%
p < 0.0001
235.56 ± 64.65 47%
p < 0.0001




10 176.80 ± 33.43 55.05%
p < 0.0001
208.00 ± 74.95 53.2%
p < 0.0001
14.40 ± 4.30 57.37%
p < 0.001.
All groups received pIL-12 at the prime.
p-value compared to pVAX by one-way ANOVA and Turkey’s post-test.
No significant difference between the third and the fourth groups.
However, the use of integrated control strategies that incorporate
a schistosome vaccine that significantly reduces passage of eggs
from buffalo and cattle will aid these long-term schistosome
control strategies (36–38). The level of efficacy required for
the transmission blocking schistosome vaccine to help reduce
prevalence of schistosomiasis has been estimated to be 45–
50% reduction in fecal eggs (4). Such a vaccine could be
incorporated as part of a multi-component integrated control
program (39).
Our previous studies in Hunan province evaluated the efficacy
of two vaccine candidates (SjTPI and SjC23) as three-dose
plasmid DNA vaccines against S. japonicum in water buffalo
(16, 19). Mathematical modeling suggests that either of these
two vaccines, in combination with human chemotherapy, could
lead to a significant reduction in schistosome transmission
(3, 16). Here, we report the results from four recent vaccine
trials performed at the same site with the goal of reducing
the vaccine regimen from three to two vaccinations, coincident
with increasing vaccine efficacy. Focusing on eventual large scale
production of these vaccines we initially compared GLP grade
plasmid DNA vaccines to lab produced plasmid DNA vaccines.
GLP plasmid DNAs are better quality and a necessary step
toward GMP product. Large scale production by GLP/GMP
capable contractors is also less expensive than lab grade produced
plasmid DNA vaccines. The results from Trial 1, shown in
Figure 2, demonstrate that there is no statistical difference in
vaccine efficacy in buffalo vaccinated with GLP grade SjC23 DNA
vaccines vs. vaccinated with lab-produced SjC23 DNA vaccines.
Thus, if plasmid DNA vaccines are to eventually be part of a
vaccine regimen employing pSjC23 and/or pSjCTPI schistosome
vaccines, cost-effective GMP production will benefit scale up
for future vaccine trials. We were surprised by the overall low
levels of protective efficacy induced by either vaccine in Trial
1. The level of efficacy observed in Trial 1 is approximately
50% lower than previously reported by us, and 50% lower than
seen in Trials 2 and 3 reported in this study. The data from
Trials 2 and 3 are closer to those previously reported for SjC23
DNA vaccine. We do not have an explanation as to why the
level of efficacy in Trial 1 was lower than that seen in the
other trials
In Trial 2 we tested for an effect of the prime-boost
interval, comparing a 1 month interval to a 3 month interval.
Surprisingly, increasing the interval between vaccine doses to
3 months did not increase efficacy as we hypothesized. In fact,
although the differences between groups are not significant,
the 1 month interval group had a trend toward higher levels
of efficacy in all parameters measured as compared to the
3 month interval group, Figure 2. As expected, IL-12 as an
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FIGURE 5 | Analysis of the humoral immune response to heterologous vaccine regimen. (A) Western Blot analysis of individual serum samples obtained from
vaccinated animals from each group prior to challenge infection. Sera from animals primed with pVAX and boosted with pVAX (lanes 1–4) or primed with pVAX and
boosted with rSjC23 and rSjCTPI (lanes 5–8) did not react with rSjC23 (left panel) or rSjCTPI (right panel). Sera from animals primed with pSjC23-Hsp70 DNA vaccine
and boosted with rSjC23 (lanes 9-12) elicited specific antibody responses with rSjC23, approximate MW of fusion protein is 26kDa (left panel) but not with rSjTPI,
approximate MW of fusion protein is 31 kDa (right panel). Sera from animals in group 4 can elicit immune responses to both specific antigens rSjC23 (left panel, lanes
13-16) and rSjTPI (right panel, lanes 13-20). (B) Total IgG antibodies for all individual animals were analyzed by ELISA. Serum samples were obtained at 4 days prior to
prime, 2 days prior challenge infection, and 2 days prior to perfusion. Left panel: anti-SjC23; right panel: anti-SjTPI. Values are expressed as means ± SE of the OD
values of all animals within the same group. *p < 0.05, ****p < 0.0001, analyzed with two-way ANOVA.
adjuvant is proved to be important for the three-dose SjC23
DNA vaccine if protection levels of 40–50% are minimum
targets of vaccine efficacy. Of note, although the use of pIL-12
plasmid during the prime increased efficacy in all parameters
measured, the differences in level of efficacy between the
pSjC23 vaccinated group and the pIL-12+pSjC23 groups were
not significant.
The final approach to increase vaccine efficacy and reduce
the regimen to two doses, was to employ a heterologous prime-
boost vaccination strategy. Here plasmid DNA vaccines are
used for the with recombinant protein antigens used for the
boost. Heterologous prime-boost strategy has been successfully
applied to many different types of diseases in animal models,
including acquired immune deficiency syndrome (AIDS) (40),
Japanese encephalitis virus (33) and malaria (41), and have
shown greater efficacy than the homologous prime.. Here we
compared prime with pIL-12+SjC23, boost with recSjC23 to
buffalo that were primed with pIL-12+SjC23+SjCTPI plasmid
DNAs, then boosted with both recSjCTPI+recSjCTPI in saline
and no adjuvant. This work led to two important observations.
First, using SjC23 we demonstrated that the heterologous prime-
boost, two-dose regimen induced levels of efficacy similar to
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that reported by us using a 3-dose plasmid DNA vaccine
regimen (16, 19). Second, by employing both antigens for the
plasmid DNA prime and the recombinant protein boost, we
increased levels of efficacy further, resulting in a 55% reduction
in adult worms and 53% reduction in eggs/gram liver compared
to levels in control vaccinated buffalo. These are the highest
levels of vaccine efficacy observed by us to date and this
was achieved using a simple prime-boost regimen without
addition of any adjuvant or delivery vehicle for the recombinant
protein boost.
Several schistosome vaccines have been developed, all
providing partial protection against Schistosoma infection.
The majority of schistosome vaccines reduce adult worm
burdens by <50% (42). Further, the majority of these
vaccines have only been evaluated for efficacy in genetically
identical inbred mice. The SjCTPI Heterologous prime-
boost vaccine is currently being field-tested in bovines
under natural challenge infection conditions in Samar, the
Philippines as part of an integrated control package involving
bovine vaccination, chemotherapy, and snail control (7).
The linking of vaccination with chemotherapy would reduce
overall morbidity and limit the impact of re-infection. Such
a novel control program for schistosomiasis would improve
significantly on the current strategy, which is based on
chemotherapy alone.
Overall, our data provides considerable optimism toward
the development of schistosome vaccines that are efficacious
in natural, outbred hosts. Further, as these two vaccines
can be further optimized by inclusion of adjuvant with
the recombinant proteins, it is likely efficacy will further
increase. This study also demonstrates how international
team collaborations contribute to the development of effective
vaccines for schistosomiasis. New antigen formulation and
delivery methods of these vaccine are currently being tested
in the Philippines. We believe that eventually, addition of
effective schistosome vaccines as components of integrated
control will be what is needed for long term control
of disease.
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